Yes, certain GLP-1 receptor agonists (liraglutide, injectable semaglutide and dulaglutide) have demonstrated cardiovascular benefits in major trials, including reduced risk of heart attack, stroke and cardiovascular death in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
Ngun gc ca Glutathione l t gan, t thnh phn ny c sn sinh tip khp cc c quan b phn ca c th
A clinic that skips this session removes the most valuable part of the process
HPG axis central effects: hypothalamus and pituitary Evidence on the potential neuroendocrine actions of GLP-1 on HPG axis was provided by an in vitro study in a rodent hypothalamic neuronal cell line (GT1-7) that reported a dose-dependent stimulating effect of GLP-1 on GnRH release, in association with a prompt increase in the plasma LH levels following the intracerebroventricular injection of GLP-1 in male rats [34]
Reassessing the cardiovascular safety of febuxostat: implications of the febuxostat versus allopurinol streamlined trial
Protein targets Aim for 1.6-2.2 grams of protein per kilogram of body weight daily
